Actuate Therapeutics (ACTU) vs Context Therapeutics (CNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Context Therapeutics (CNTX) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 85.3% versus a loss of 96.4%. Context Therapeutics is the larger company by market cap ($14.7 million vs $13.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | CNTX |
|---|---|---|
| Share price | $0.2253 | $0.16 |
| Market cap | $13.60M | $14.70M |
| 1-day change | +5.38% | -5.10% |
| YTD return | -96.32% | -89.12% |
| 1-year return | -96.43% | -85.32% |
| 5-year return | — | -96.86% |
| EPS (TTM) | $-0.76 | $-0.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-22.23M | $-36.12M |
| 52-week high | $7.90 | $3.62 |
| 52-week low | $0.174 | $0.153 |
| Distance from 52-week high | -97.15% | -95.58% |
| Analyst consensus | none | none |
| Avg. price target upside | +5084.20% | +2418.75% |
| Average volume | 807.24K | 1.42M |
| Shares outstanding | 60.38M | 91.88M |
| Employees | 12 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTX has outperformed ACTU by 11.1 percentage points over the past year.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
ACTU vs CNTX FAQ
Which is bigger, Actuate Therapeutics or Context Therapeutics?
Context Therapeutics (CNTX) is larger, with a market capitalization of $14.70M compared with $13.60M for Actuate Therapeutics (ACTU).
Which stock has performed better over the past year, ACTU or CNTX?
CNTX returned -85.32% over the past 12 months, compared with -96.43% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Context Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.